("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF). The study, led by Professor Huaping Dai ...

Gain insights, see trends and get real-time updates when you securely link or manually add your brokerage accounts.